SCHEMBL5048482

SCHEMBL5048482

Cc1cccc(-n2nc(C(C)(C)C)cc2C(N)=O)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK2 O43353 1/20 0.58
GRN P28799 1/20 0.58
SORT1 Q99523 1/20 0.58
MAPK14 Q16539 12/20 0.57
MAPK13 O15264 6/20 0.57
MAPK12 P53778 6/20 0.57
MAPK11 Q15759 6/20 0.57
DDR2 Q16832 3/20 0.54
MAPK9 P45984 3/20 0.54
CDK8 P49336 2/20 0.49
AURKA O14965 1/20 0.48
CSF1R P07333 1/20 0.48
RET P07949 1/20 0.48
LTK P29376 1/20 0.48
CSNK1A1 P48729 1/20 0.48
CLK2 P49760 1/20 0.48
CDK5 Q00535 1/20 0.48
ACVR1 Q04771 1/20 0.48
CLK4 Q9HAZ1 1/20 0.48
ALDH1A1 P00352 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22417059 0.88 KLKB1 (0.58) RIPK2KLKB1
SCHEMBL16749343 0.88 GRN (0.76) RIPK2GRNSORT1MAPK14MAPK13
SCHEMBL4718807 0.86 GRN (0.78) GRNSORT1MAPK14MAPK13MAPK12
SCHEMBL1600416 0.86 CDK8 (0.64) GRNSORT1MAPK14MAPK13MAPK12
SCHEMBL15428639 0.83 ALDH1A1 (0.60) RIPK2ALDH1A1KMT2A
SCHEMBL16749217 0.82 GRN (0.53) RIPK2GRNSORT1MAPK14MAPK13
SCHEMBL2707992 0.81 GRN (0.52) GRNSORT1MAPK14MAPK13MAPK12
SCHEMBL2725769 0.80 GRN (0.51) GRNSORT1MAPK14MAPK13MAPK12
SCHEMBL23401692 0.80 MAPK14 (0.57) RIPK2GRNSORT1MAPK14MAPK13
SCHEMBL2788301 0.79 GRN (0.58) GRNSORT1MAPK14MAPK13MAPK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110301157-A1 BICYCLIC AMIDES AS KINASE INHIBITORS NOVARTIS AG 2011-12-08 US claimed
US-20080287427-A1 Bicyclic Amides as Kinase Inhibitors NOVARTIS AG (CH) 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301157-A1 BICYCLIC AMIDES AS KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K19 RIPK2 482/4885GRN 2663/4885SORT1 4864/4885
US-20080287427-A1 Bicyclic Amides as Kinase Inhibitors MAP3K20, MAP3K1, MAP3K19 RIPK2 468/4885GRN 2479/4885SORT1 4871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.